May 7, 2026 · Form 4 insider transaction
EVNIN LUKE sold 79,086 shares of Werewolf Therapeutics, Inc. at $0.63 per share, a transaction worth $49.8K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 0 days after the transaction.
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.; The shares were sold as follows: 8,473 by AM LLC, 53,499 by BV 2014, 3,568 by BV 2014(B), 1,841 by AM BV2014 and 11,705 by MPM OIF.; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.667 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.; MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.; The shares are held as follows: 169,147 by AM LLC, 1,067,960 by BV 2014, 71,230 by BV 2014(B), 36,757 by AM BV2014 and 233,655 by MPM OIF.